Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells

Molecular and Cellular Biochemistry

Volumn 386, Issue 1-2, 2014, Pages 63-71

  Qu, Chen ^a,b   Zhang, Weijia ^a   Zheng, Guopei ^a   Zhang, Zijuan ^a   Yin, Jiang ^a   He, Zhimin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

Breast cancer; EMT; Metformin; Multidrug resistance

Indexed keywords

DOXORUBICIN; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIZATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; METFORMIN; PROTEIN KINASE INHIBITORS;

EID: 84891532512     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1845-x     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
2. Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM (2009) ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 9(1-2):136-144. doi: 10.1159/000178884
3. Zheng G, Peng F, Ding R, Yu Y, Ouyang Y, Chen Z, Xiao Z, He Z (2010) Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis. J Cancer Res Clin Oncol 136(10):1477-1488. doi: 10.1007/s00432-010-0805-z
4. Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, He Z (2012) 14-3-3Sigma regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. FEBS Lett 586(2):163-168. doi: 10.1016/j.febslet.2011.11.034
5. Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, Yin J, Yu Y, He Z (2012) Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 417(2):679-685. doi: 10.1016/j.bbrc.2011.11.142
6. Berstein LM, Boyarkina MP, Teslenko SY (2012) Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Med Oncol (Northwood, London, England) 29 (2):1308-1313. doi: 10.1007/s12032-011-9840-0
7. Kourelis TV, Siegel RD (2012) Metformin and cancer: new applications for an old drug. Med Oncol (Northwood, London, England) 29 (2):1314-1327. doi: 10.1007/s12032-011-9846-7
8. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334(9):574-579. doi: 10.1056/nejm199602293340906
9. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S (2011) Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2:e199. doi: 10.1038/cddis.2011.86
10. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67(14):6745-6752. doi: 10.1158/0008-5472.can-06-4447
11. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA (2010) Metformin against TGFbeta-induced epithelial-to- mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle (Georgetown, Tex) 9(22):4461-4468
12. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69(19):7507-7511. doi: 10.1158/0008-5472.can-09-2994
13. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (Georgetown, Tex) 8(13):2031-2040
14. Zhuang Y, Miskimins WK (2011) Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 9(5):603-615. doi: 10.1158/1541-7786.mcr-10-0343
15. Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71(9):3196-3201. doi: 10.1158/0008-5472.can-10-3471
16. Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17(12):3993-4005. doi: 10.1158/1078-0432.ccr-10-2243
17. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL (2012) Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis 3:e275. doi: 10.1038/cddis.2012.13
18. Zhang Y, Wang Y, Bao C, Xu Y, Shen H, Chen J, Yan J, Chen Y (2012) Metformin interacts with AMPK through binding to gamma subunit. Mol Cell Biochem 368(1-2):69-76. doi: 10.1007/s11010-012-1344-5
19. Bhowmik A, Das N, Pal U, Mandal M, Bhattacharya S, Sarkar M, Jaisankar P, Maiti NC, Ghosh MK (2013) 2,2′-Diphenyl-3,3′-diindolylmethane: a potent compound induces apoptosis in breast cancer cells by inhibiting EGFR pathway. PLoS ONE 8(3):e59798. doi: 10.1371/journal.pone.0059798
20. Yao J, Bi HE, Sheng Y, Cheng LB, Wendu RL, Wang CH, Cao GF, Jiang Q (2013) Ultraviolet (UV) and hydrogen peroxide activate ceramide-ER stress-AMPK signaling axis to promote retinal pigment epithelium (RPE) cell apoptosis. Int J Mol Sci 14(5):10355-10368. doi: 10.3390/ijms140510355
21. Esfahanian N, Shakiba Y, Nikbin B, Soraya H, Maleki-Dizaji N, Ghazi-Khansari M, Garjani A (2012) Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol Med Rep 5(4):1068-1074. doi: 10.3892/mmr.2012.753
22. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 8(8):e71583. doi: 10.1371/journal.pone.0071583
23. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL (2013) Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 6(10):3018-3026. doi: 10.2337/dc12-2535
24. Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, Wang M, Zhang Z, Qin C, Hua L, Yin C, Shao P (2013) miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem 379(1-2):69-75. doi: 10.1007/s11010-013-1628-4
25. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD (2009) Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15(8):2657-2665. doi: 10.1158/1078-0432.ccr-08-2372
26. Raimondi C, Gianni W, Cortesi E, Gazzaniga P (2010) Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. Curr Cancer Drug Targets 10(5):496-508
27. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34):4741-4751. doi: 10.1038/onc.2010.215
28. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, Kim YS, Lee S, Trepel J, Srinivasan R, Bratslavsky G, Yang Y, Linehan WM, Rouault TA (2011) The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20(3):315-327. doi: 10.1016/j.ccr.2011.07.018
29. Ramnanan CJ, McMullen DC, Groom AG, Storey KB (2010) The regulation of AMPK signaling in a natural state of profound metabolic rate depression. Mol Cell Biochem 335(1-2):91-105. doi: 10.1007/s11010-009-0246-7
30. Kim I, He YY (2013) Targeting the AMP-activated protein kinase for cancer prevention and therapy. Frontiers Oncol 3:175. doi: 10.3389/fonc.2013.00175
31. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101(10):3329-3335. doi: 10.1073/pnas.0308061100
32. Kaur M, Deep G, Jain AK, Raina K, Agarwal C, Wempe MF, Agarwal R (2013) Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells. Carcinogenesis 34(7):1585-1592. doi: 10.1093/carcin/bgt081
33. Huo HZ, Wang B, Qin J, Guo SY, Liu WY, Gu Y (2013) AMP-activated protein kinase (AMPK)/Ulk1-dependent autophagic pathway contributes to C6 ceramide-induced cytotoxic effects in cultured colorectal cancer HT-29 cells. Mol Cell Biochem 378(1-2):171-181. doi: 10.1007/s11010-013-1608-8
34. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R (2012) TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 125(Pt 5):1259-1273. doi: 10.1242/jcs.095299
35. Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E (2013) Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol 71(5):1297-1307. doi: 10.1007/s00280-013-2129-6
36. Lee JH, Kim JH, Kim JS, Chang JW, Kim SB, Park JS, Lee SK (2013) AMP-activated protein kinase inhibits TGF-beta-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol 304(6):F686-F697. doi: 10.1152/ajprenal.00148.2012
37. Burris HA 3rd (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71(4):829-842. doi: 10.1007/s00280-012-2043-3
38. Berk L, Mita MM, Kreisberg J, Bedrosian CL, Tolcher AW, Clackson T, Rivera VM (2012) Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. Cancer Chemother Pharmacol 69(5):1369-1377. doi: 10.1007/s00280-011-1813-7
39. Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K, Tamura T (2012) Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 69(4):1099-1105. doi: 10.1007/s00280-011- 1788-4